Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics

Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly 
Develop microRNA-Based Diagnostics and Therapeutics for Rare
Alliance Combines Industry Leading microRNA Biomarker and Target
Discovery Platform With Proprietary microRNA Drug Discovery Engine 
PRINCETON, NJ and REHOVOT, ISRAEL and BOSTON, MA -- (Marketwired) --
04/02/14 --  Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading
developer and provider of microRNA-based molecular diagnostics and
therapeutics, and Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading
nucleic acid-based drug discovery and development company focused on
rare diseases, jointly announced that they had established a
strategic alliance, wherein the companies will collaborate to
identify and develop microRNA-based products designed to diagnose and
treat various neuromuscular diseases and dystrophies.  
The Alliance is exclusive as it relates to neuromuscular diseases and
dystrophies, with both Companies free to develop and collaborate
outside this field both during and after the terms of the Alliance.
The Companies' initial efforts are expected to be focused on Becker
and Duchenne muscular dystrophies as well as myotonic dystrophy.
Financial terms and other details of the agreement are not being
disclosed at this time.  
Under the terms of the Alliance, Rosetta will apply its industry
leading microRNA discovery expertise for the identification of
microRNAs involved in the various dystrophy diseases. If the microRNA
is determined to be correlative to the disease, Rosetta may further
develop the microRNA into a diagnostic for patient identification and
stratification. If the microRNA is determined to be involved in the
disease pathology and represents a potential therapeutic target,
Marina may develop the resulting microRNA-based therapeutic for
clinical development.  
"We are delighted to have the opportunity to apply our leading-edge
microRNA expertise with Marina's single- and double-stranded nucleic
acid therapeutics in order to isolate specific microRNA biomarkers
for the development of diagnostics and therapies for a variety of
dystrophies. These rare diseases remain a significant unmet medical
need," stated Kenneth A. Berlin, President and Chief Executive
Officer of Rosetta Genomics. "Targeted diagnostics to identify
potential responders/non-responders for specific therapies would mark
a significant advance for these patients as dystrophies are
degenerative diseases that accelerate over time. In addition, current
treatment options are sub-optimal and costly. We believe the
development of a diagnostic that can accurately predict response to
therapy will bring effective treatment to dystrophy patients earlier
and with significant cost savings." 
"The Alliance is a perfect match of cutting-edge technologies,"
stated J. Michael French, President and CEO of Marina Biotech.
"Rosetta brings to the Alliance world class expertise in the
development of microRNA diagnostics. Importantly, Rosetta can
potentially identify novel microRNA targets for further development
into clinical candidates. Marina is in the unique position to
capitalize on Rosetta's expertise by utilizing Rosetta's
microRNA-based diagnostics for patient identification and
stratification in Marina's clinical development programs and by
utilizing Marina's proprietary chemistries and delivery technologies
to advance novel microRNA-based therapeutics -- both single-stranded
microRNA antagonists and double-stranded microRNA mimics -- into the
clinic. We believe our SMARTICLES(R) is the only delivery technology
currently in clinical development that is delivering both
single-stranded oligonucleotides and double-stranded microRNA mimics.
We believe this delivery technology, combined with our
conformationally restricted nucleotide chemistry, will permit us to
develop best-in-class microRNA antagonists and mimics. Our ability to
work with both modalities is potentially critically important in the
treatment of multi-system diseases such as myotonic dystrophy. While
current technologies are limited by either a single-stranded or a
double-stranded approach, Marina can pursue whichever nucleic acid
modality most effectively treats these debilitating diseases." 
"This latest strategic alliance underscores the versatility of
Rosetta's microRNA biomarker platform for the identification of
specific microRNA signatures for a variety of indications and
applications and positions Rosetta Genomics as the partner of choice
for such collaborations," added Mr. Berlin. "Importantly, these
partnerships represent our company's third platform for revenue
growth. Moving forward, we expect to enter into additional agreements
as we seek to monetize our leading microRNA biomarker platform." 
About Neuromuscular Disorders and Dystrophies
disorders affect the nerves that control voluntary muscles, such as
those that control the arms and legs. Nerve cells, also called
neurons, send messages that control these muscles. When the neurons
become unhealthy or die, communication between the nervous system and
muscles breaks down. As a result, muscles weaken and waste away.
Likewise, dystrophies are progressive degenerative disorders
affecting skeletal muscles. In both cases, the diseases can often
effect other organ systems such as the heart and central nervous
system. Many neuromuscular diseases and almost all dystrophies are
genetic, which means there is a mutation in genes which in many cases
is passed from family member to family member. Although a cure for
these disorders may present itself in the future, currently the goal
of drug development efforts is to improve symptoms, increase mobility
and increase the individual's lifespan. 
About Marina Biotech, Inc.
 Marina Biotech is an oligonucleotide
therapeutics company with broad drug discovery technologies providing
the ability to develop proprietary single and double-stranded nucleic
acid therapeutics including siRNAs, microRNA mimics, antagomirs, and
antisense compounds, including messengerRNA therapeutics. These
technologies were built via a roll-up strategy to discover and
develop different types of nucleic acid therapeutics in order to
modulate (up or down) a specific protein(s) which is either being
produced too much or too little thereby causing a particular disease.
We believe that the Marina Biotech technologies have unique strengths
as a drug discovery engine for the development of nucleic acid-based
therapeutics for rare and orphan diseases. Further, we believe Marina
Biotech is the only company in the sector that has a delivery
technology in human clinical trials with differentiated classes of
payloads, through licensees ProNAi Therapeutics and Mirna
Therapeutics, delivering single-stranded and double-stranded nucleic
acid payloads, respectively. Our novel chemistries and other delivery
technologies have been validated through license agreements with
Roche, Novartis, Monsanto, and Tekmira. The Marina Biotech pipeline
currently includes a clinical program in Familial Adenomatous
Polyposis (a precancerous syndrome) and a preclinical program in
myotonic dystrophy. Marina Biotech's goal is to improve human health
through the development of RNAi- and oligonucleotide-based compounds
and drug delivery technologies that together provide superior
therapeutic options for patients. Additional information about Marina
Biotech is available at  
About Rosetta Cancer Testing Services 
 Rosetta Cancer Tests are a
series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test(TM) can accurately
identify the primary tumor type in primary and metastatic cancer
including cancer of unknown or uncertain primary (CUP). Rosetta
Mesothelioma Test(TM) diagnoses mesothelioma, a cancer connected to
asbestos exposure. The Rosetta Lung Cancer Test(TM) accurately
identifies the four main subtypes of lung cancer using small amounts
of tumor cells. The Rosetta Kidney Cancer Test(TM) accurately
classifies the four most common kidney tumors: clear cell renal cell
carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.
Rosetta's assays are designed to provide objective diagnostic data;
it is the treating physician's responsibility to diagnose and
administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the
Rosetta Cancer Origin Test(TM), 60,000 from the Rosetta Mesothelioma
Test(TM), 65,000 from the Rosetta Kidney Cancer Test(TM) and 226,000
patients from the Rosetta Lung Cancer Test(TM). The Company's assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. For more information, please visit Parties interested in ordering the test can
contact Rosetta Genomics at (215) 382-9000 ext. 309. 
About Rosetta Genomics
 Founded in 2000, Rosetta's integrative
research platform combining bioinformatics and state-of-the-art
laboratory processes has led to the discovery of hundreds of
biologically validated novel human microRNAs. Building on its strong
patent position and proprietary platform technologies, Rosetta is
working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic
tools and therapeutics. Rosetta currently commercializes a full range
of microRNA-based molecular diagnostics. Rosetta's cancer testing
services are commercially available through its Philadelphia-based
CAP-accredited, CLIA-certified lab. For more information, please
Marina Biotech Forward-Looking Statements
 Statements made in this
news release may be forward-looking statements within the meaning of
Federal Securities laws that are subject to certain risks and
uncertainties and involve factors that may cause actual results to
differ materially from those projected or suggested. Factors that
could cause actual results to differ materially from those in
forward-looking statements include, but are not limited to: (i) the
ability of Marina Biotech to obtain additional funding; (ii) the
ability of Marina Biotech to attract and/or maintain manufacturing,
research, development and commercialization partners; (iii) the
ability of Marina Biotech and/or a partner to successfully complete
product research and development, including preclinical and clinical
studies and commercialization; (iv) the ability of Marina Biotech
and/or a partner to obtain required governmental approvals; and (v)
the ability of Marina Biotech and/or a partner to develop and
commercialize products prior to, and that can compete favorably with
those of, competitors. Additional factors that could cause actual
results to differ materially from those projected or suggested in any
forward-looking statements are contained in Marina Biotech's most
recent filings with the Securities and Exchange Commission. Marina
Biotech assumes no obligation to update or supplement forward-looking
statements because of subsequent events. 
Rosetta Forward-Looking Statement Disclaimer
 Various statements in
this release concerning Rosetta's future expectations, plans and
prospects, including without limitation, statements relating to
potential revenue growth, the expectation to enter into additional
similar agreements as Rosetta seeks to monetize its leading microRNA
platform and expertise, Rosetta identifying novel microRNA targets
for further development into clinical candidates and the
collaboration resulting in successful identification and development
of microRNA-based products, constitute forward-looking statements for
the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, including those risks more
fully discussed in the "Risk Factors" section of Rosetta's Annual
Report on Form 20-F for the year ended December 31, 2013 as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be
relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any forward-looking
statements unless required by law. 
Marina Biotech Contact: 
J. Michael French
President and CEO
(425) 892-4322 
Rosetta Genomics Contact:  
Ken Berlin
President & CEO 
(609) 419-9000, ext. 1326 
Rosetta Genomics Investor Contacts: 
Anne Marie Fields
(212) 838-3777
Bruce Voss
(310) 691-7100 
Press spacebar to pause and continue. Press esc to stop.